ADIM
MRNS

Alpha DNA Investment Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Alpha DNA Investment Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49,664
Closed -$540K – 262
2023
Q4 		$540K Sell
49,664
-27,419
-36% -$205K 0.21% 101
2023
Q3 		$621K Buy
+77,083
New +$641K 0.25% 82

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Alpha DNA Investment Management's MRNS Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2024, closing a stake of 49,664 shares — an estimated $540K sold.

Alpha DNA Investment Management first reported a position in MRNS in Q3 2023 and held it in 2 quarters. The position peaked at $621K in Q3 2023. 112 funds tracked by Wall St. Rank hold MRNS as of Q1 2024.

  • Alpha DNA Investment Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 49,664 Marinus Pharmaceuticals, Inc shares in Q1 2024, an estimated $540K.
  • Alpha DNA Investment Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2023 and held it in 2 quarters.
  • Alpha DNA Investment Management's Marinus Pharmaceuticals, Inc position peaked at $621K in Q3 2023.
  • 112 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.